pDNA Vaccines for Cancer, Autoimmune Diseases, and Infectious Diseases

The present inventive concept leverages the core technology of synthetic pDNA vaccines against COVID-19 to develop novel treatments and diagnostic tools for cancer, autoimmune diseases, and infectious diseases.

The original patent disclosed synthetic pDNA vaccines against COVID-19, demonstrating their potential in inducing immune responses. However, the patent's scope was limited to SARS-CoV-2. The present inventive concept addresses the need for novel applications of pDNA vaccines in distinct fields, including cancer, autoimmune diseases, and infectious diseases, where conventional treatments often have limited efficacy or significant side effects.

The inventive concept involves engineering pDNA vaccines to express fusion proteins comprising tumor-associated antigens, self-antigens, or pathogen-specific antigens, and a SARS-CoV-2 S protein epitope. These pDNA vaccines can induce immune responses against the respective antigens, providing a therapeutic or prophylactic approach for cancer, autoimmune diseases, and infectious diseases. The system, method, composition, device, and kit claims outline specific implementations of this concept, highlighting its versatility and broad applicability.

The new claims introduce a novel combination of pDNA vaccine technology with distinct disease areas, creating an inventive step beyond the original patent's scope. The fusion of a SARS-CoV-2 S protein epitope with various antigens enables the pDNA vaccines to harness the immune system's response to SARS-CoV-2 and redirect it against the targeted disease.

Alternative embodiments may include using different SARS-CoV-2 epitopes, varying the antigen composition, or incorporating additional immune-stimulatory elements. Variations may also involve adapting the pDNA vaccine platform for specific disease indications or combining it with other therapeutic approaches.

The inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, with potential applications in cancer, autoimmune diseases, and infectious diseases. The market for these applications is substantial, with an estimated global value exceeding tens of billions of dollars.